This metabolic inhibition was further corroborated by the enzymatic activity assays, which showed a significant reduction in lactate dehydrogenase (LDH) and pyruvate dehydrogenase (PDH) activities in all three melanoma cell lines when treated with the two compounds (Figure 2F). The gene discussed is PDP1; the disease is melanoma.